Tagged with BIOTEC

Canada Stefan Larson, CEO of Northern Biologics, explains the major milestones for Northern Biologics over the past three years, his personal motivation for starting a biotech company, their collaboration with Celgene, and his thoughts on the strengths and areas for growth within the Canadian biotech industry. Stefan, three years into the…

Brazil Heraldo Marchezini, CEO of the Brazilian biotech company Biomm and one of the leading executives in the Brazilian biopharmaceutical sector, provides insights into the eye-catching international partnerships recently signed by this ambitious company and documents Biomm’s vision to develop a balanced portfolio combining very innovative biologicals and leading biosimilars in…

Canada Clarissa Desjardins is the founder and CEO since 2011 of Canadian biotech success story, Clementia Pharmaceuticals. She explains the different milestones of her company and her priorities moving forward. She also gives her insights on the entrepreneurship environment in Canada and advice on how to make it even more compelling…

Bulgaria Ana Tsakova, managing director at Merck Bulgaria, emphasizes the duty of the industry to raise the bar of treatment quality in the country and shows the commitment of Merck in this regard to collaborate with both physicians and patients in key therapeutic areas such as oncology, fertility, multiple sclerosis, diabetes,…

Brazil Guilherme Maradei, managing director of Merck Brazil and general manager Biopharma, documents the eye-catching growth that the Brazilian affiliate has been experiencing over the past two years and provides insights into the outstanding footprint of the company in Brazil as well as its remarkable ambitions and achievements when it comes…

Switzerland In an exclusive interview, Jean-Paul Clozel, former head of Actelion and now CEO of exciting biotech newcomer Idorsia, discusses his new company’s unique drug discovery methodology, the pressure of past success, and how he hopes to usher in a new era of collaboration to tackle disease.   In August 2016,…

Brazil Luciano Finardi, general manager of Celgene Brazil, describes the unrivalled commitment of the company to Brazilian patients and documents the remarkable dedication of Celgene to registering its flagship product in Brazil, as well as the company’s willingness to cope with the country’s unpredictability while establishing its operation in Brazil. Celgene…

Brazil Mauro Loch, general manager of Amgen Brazil, documents the eye-catching turnaround of the affiliate since the beginning of his tenure and provides insights into the company’s unique positioning in Brazil, the outstanding performance of recently launched products, as well as his main priorities to further increase access to Amgen’s life-changing…

Tunisia Hammadi Ayadi, CEO of Sidi Thabet BiotechPole, proudly introduces the launch of the site’s incubator and announces the soon-to-come opening of the company cluster. This will provide a platform for the fusion of theoretical research and technical knowhow and aid the development of the first biotech drug made in Tunisia…

Bulgaria Krassimira Chemishanska, country director at Amgen Bulgaria, showcases the role of innovative players in the country, the importance of moving towards a value-based assessment system, and how Amgen has performed since its entrance to the Bulgarian market back in 2009. You opened the Bulgarian affiliate back in 2009. How challenging…

Canada Andrew Casey, President and CEO of BIOTECanada, the national biotech association, provides an update on the Canadian biotech landscape, the strength of the Canadian R&D ecosystem, the growing investor community (both Canadian and foreign) looking to Canada as an untapped land of opportunities, and his hope to position Canada as…

Tunisia Hechmi Louzir, general manager of the Institut Pasteur in Tunis (IPT), details the crucial role that the IPT plays in the development of the Tunisian health sector, his wide-ranging responsibilities as general manager, the increasing importance of building new partnerships between the private and public sectors, and the Institute’s ambition…